International Clinical Trial: A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214766) titled 'A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants' on Oct. 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Genentech, Inc.

Condition: Healthy Participants

Intervention: Drug: Trastuzumab

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 17, 2025

Target Sample Size: 312

To know more, visit https://clinicaltrials.gov/study/NCT07214766

Published by HT Digital ...